A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction

Kasper Kyhl, Jacob Lønborg, Niels Grove Vejlstrup, Henning Kelbæk, Steffen Helqvist, Lene Holmvang, Erik Jørgensen, Kari Saunamäki, Hans Erik Bøtker, Peter Clemmensen, Lars Køber, Marek Treiman, Thomas Engstrøm

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

AIMS: We aimed to assess the effect of exenatide treatment as an adjunct to primary percutaneous coronary intervention (PCI) on long-term clinical outcome.

METHODS AND RESULTS: We performed a post hoc analysis in 334 patients with a first STEMI included in a previous study randomised to exenatide (n=175) or placebo (n=159) as an adjunct to primary PCI. The primary endpoint was a composite of all-cause mortality and admission for heart failure during a median follow-up of 5.2 years (interquartile range: 5.0-5.5). Secondary endpoints were all-cause mortality and admission for heart failure, individually. The primary composite endpoint occurred in 24% in the exenatide group versus 27% in the placebo group, p=0.44 (HR 0.80, p=0.35). Admission for heart failure was lower in the exenatide (11%) compared to the placebo group (20%) (HR 0.53, p=0.042). All-cause mortality occurred in 14% in the exenatide group versus 9% in the placebo group (HR 1.45, p=0.20).

CONCLUSIONS: In this post hoc analysis of patients with a STEMI, treatment with exenatide at the time of primary PCI did not reduce the primary composite endpoint or the secondary endpoint of all-cause -mortality. However, exenatide treatment reduced the incidence of admission for heart failure.

OriginalsprogEngelsk
TidsskriftEuroIntervention
Vol/bind12
Udgave nummer4
Sider (fra-til)449-55
ISSN1774-024X
DOI
StatusUdgivet - 20. jul. 2016
Udgivet eksterntJa

Fingeraftryk Dyk ned i forskningsemnerne om 'A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction'. Sammen danner de et unikt fingeraftryk.

Citationsformater